 "medicine, drug, drugs, tablets")
Shares of Granules India have rallied 7% to Rs 104 per share on the BSE in early morning trade after the pharmaceuticals company said Granules Pharmaceuticals Inc., a wholly owned subsidiary of the company, received US health regulatory approval for generic Methylergonovine tablets.
“The United States Food and Drug Administration (US-FDA) has approved its Abbreviated New Drug Applications (ANDA) for Methylergonovine 0.2 mg Tablets. The ANDA was filed by Granules Pharmaceuticals Inc., a wholly owned subsidiary of Granules India. The approved ANDA is the bioequivalent to the reference listed drug product (RLD), Methergine 0.2 MG,” the company said in a press release.
Methylergonovine is a semi—synthetic ergot alkaloid used for the prevention and control of postpartum haemorrhage, it added.
Till 09:39 am; a combined 2.6 million equity shares have already changed hands on the counter in first 30 minutes of trade on the BSE and NSE.
“The United States Food and Drug Administration (US-FDA) has approved its Abbreviated New Drug Applications (ANDA) for Methylergonovine 0.2 mg Tablets. The ANDA was filed by Granules Pharmaceuticals Inc., a wholly owned subsidiary of Granules India. The approved ANDA is the bioequivalent to the reference listed drug product (RLD), Methergine 0.2 MG,” the company said in a press release.
Methylergonovine is a semi—synthetic ergot alkaloid used for the prevention and control of postpartum haemorrhage, it added.
Till 09:39 am; a combined 2.6 million equity shares have already changed hands on the counter in first 30 minutes of trade on the BSE and NSE.
